<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02015832</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI-002</org_study_id>
    <nct_id>NCT02015832</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI</brief_title>
  <official_title>A Single-arm Trial to Evaluate the Effectiveness of PCI of de Novo 3-vessel Disease Applying the SYNTAX Score II With Pressure Wire Functional Assessment and IVUS Guidance, Using an Everolimus-eluting Stent With Biodegradable Abluminal Coating</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Volcano Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study that aims to evaluate a new strategy using the SYNTAX II Score calculator in&#xD;
      the functional assessment of patients with new coronary 3-vessel-disease who undergo&#xD;
      percutaneous coronary intervention (PCI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the SYNTAX II Trial is to investigate the management of de-novo&#xD;
      3-vessel-disease in order to prospectively assess which patients would have at least&#xD;
      comparable short and long term clinical outcomes between coronary artery bypass graft and&#xD;
      percutaneous coronary intervention (PCI), using contemporary PCI practice. In SYNTAX II the&#xD;
      effectiveness of a contemporary stent (designed with thinner struts, biocompatible and&#xD;
      biodegradable polymer, and a limus based drug), the use of pressure wire assessment of&#xD;
      lesions to allow for ischemia-driven revascularisation, intravascular ultrasound (IVUS)&#xD;
      guidance to optimise drug eluting stent deployment, and the treatment of (chronic) total&#xD;
      occlusion lesions with contemporary techniques, will be compared against PCI practice in the&#xD;
      original SYNTAX trial. The proposed study would involve the SYNTAX Score II to prospectively&#xD;
      recruit subjects on the grounds of patient safety&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2014</start_date>
  <completion_date type="Actual">February 4, 2021</completion_date>
  <primary_completion_date type="Actual">March 28, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Composite of major adverse cardiac and cerebrovascular events (MACCE) rate compared to PCI arm of SYNTAX I</measure>
    <time_frame>1 year</time_frame>
    <description>MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause death, cerebrovascular event (stroke), documented myocardial infarction compared to the PCI arm of SYNTAX I</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death, documented target-vessel myocardial infarction and repeat target lesion revascularization at 1 year follow-up compared to the PCI arm of SYNTAX I</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of individual components of MACCE at 1 year</measure>
    <time_frame>1 Year</time_frame>
    <description>MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of MACCE and its individual components of 2-5 years period of follow-up (patient reported)</measure>
    <time_frame>2-5 Years</time_frame>
    <description>MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) - according to Universal MI definition 2012</measure>
    <time_frame>1 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>1 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction - according to Universal MI definition 2012</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction - according to Universal MI definition 2012</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction - according to Universal MI definition 2012</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction - according to Universal MI definition 2012</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Composite of MACCE at 5 years follow-up compared to coronary artery bypass graft (CABG) arm of the SYNTAX I Trial</measure>
    <time_frame>5 years</time_frame>
    <description>Exploratory endpoint. MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">454</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>3 Vessel Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <description>All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary stent</intervention_name>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>SYNERGY™ EES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Multi Slice Computed Tomography</intervention_name>
    <description>A coronary non-invasive Multi Slice Computed Tomography will be performed in patients</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>MSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>instantaneous wave-free ratio</intervention_name>
    <description>Pressure-derived, adenosine-free index on physiological assessment of stenosis severity</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>iFR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional flow reserve</intervention_name>
    <description>Pressure-derived index on physiological assessment of stenosis severity</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>FFR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravascular Ultrasound</intervention_name>
    <description>Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>IVUS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with de novo 3 vessel disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 1 stenosis, angiographic, visually determined de novo lesions with more than&#xD;
             50 percent diameter stenosis in all 3 major epicardial territories. These are left&#xD;
             descending coronary artery (LAD) and or side branch, proximal circumflex coronary&#xD;
             artery (LCX) and or side branch, right descending coronary artery (RCA) and or side&#xD;
             branch which are supplying viable myocardium without left main involvement. Patients&#xD;
             with ostial LAD or ostial CX Medina 0,0,1 or Medina 0,1,0 may be enrolled&#xD;
&#xD;
          -  Patients with hypoplastic RCA with absence of descending posterior and presence of a&#xD;
             lesion in the LAD and CX territories may be included in the trial as a 3 vessel&#xD;
             disease equivalent&#xD;
&#xD;
          -  Vessel size should be at least 1.5 mm in diameter as visually assessed in diagnostic&#xD;
             angiogram&#xD;
&#xD;
          -  Patients with&#xD;
&#xD;
               1. stable (Canadian Cardiovascular Society Class 1, 2, 3 or 4) angina pectoris&#xD;
&#xD;
               2. or unstable (Braunwald class) angina pectoris and ischemia&#xD;
&#xD;
               3. or patients with atypical chest pain or those who are asymptomatic provided they&#xD;
                  have myocardial ischemia, for example treadmill exercise test, radionuclide&#xD;
                  scintigraphy, stress echocardiography&#xD;
&#xD;
          -  All anatomical SYNTAX Scores are eligible for initial screening with the SYNTAX Score&#xD;
             II&#xD;
&#xD;
          -  Patient has been informed of the nature of the study and agrees to its provisions and&#xD;
             has provided written informed consent as approved by the Ethical Committee of the&#xD;
             respective clinical site&#xD;
&#xD;
          -  Signed Heart Team Decision Form between local cardiologist and surgeon that the&#xD;
             selected case meets all of the inclusion and exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under the age of 21 years&#xD;
&#xD;
          -  Known pregnancy at time of enrolment. Female of childbearing potential, and last&#xD;
             menstruation within the last 12 months, who are not taking adequate contraceptives.&#xD;
             Female who is breastfeeding at time of enrolment&#xD;
&#xD;
          -  Prior PCI or CABG&#xD;
&#xD;
          -  Ongoing acute myocardial infarction and enzymes (CKMB) more than 2x upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Concomitant cardiac valve disease requiring surgical therapy, reconstruction or&#xD;
             replacement&#xD;
&#xD;
          -  Single or two-vessel disease at time of Heart Team consensus&#xD;
&#xD;
          -  Participation or planned participation in another cardiovascular clinical study before&#xD;
             one year follow up is completed&#xD;
&#xD;
          -  Mental condition, psychiatric or organ cerebral disease, rendering the subject unable&#xD;
             to understand the nature, scope, and possible consequences of the study or mental&#xD;
             retardation or language barrier such that the patient is unable to give informed&#xD;
             consent and potential for non-compliance towards the requirement in the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Serruys, Prof. MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Thoraxcenter, Erasmus, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Escaned, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Carlos Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian Banning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Radcliffe Hospital, Oxford, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arie-Pieter Kappetein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thorax center, Erasmus, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Taggart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Radcliffe Hospital, Oxford. United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vasim Farooq, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester Royal Infirmary, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Center NL007</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center NL001</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center PL008</name>
      <address>
        <city>Bielsko-Biała</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center PL012</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center PL010</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center PL004</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center ES009</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center ES001</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center ES007</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad Autonoma De Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center ES012</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad Autonoma De Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center ES015</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad Autonoma De Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center ES004</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center ES016</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB014</name>
      <address>
        <city>Belfast</city>
        <state>County Antrim</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB019</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB005</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB020</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB015</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB001</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB017</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB006</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center GB013</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Latvia</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 13, 2013</study_first_submitted>
  <study_first_submitted_qc>December 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SYNTAX II Score</keyword>
  <keyword>Pressure wires</keyword>
  <keyword>instantaneous wave-free ratio</keyword>
  <keyword>fractional flow reserve</keyword>
  <keyword>intravascular ultrasound</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>multi slice computed tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 15, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

